Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

RNA, [P-deoxy-P-(dimethylamino)] (2,3-dideoxy-2,3-imino-2,3-seco) (2a?5) (C-m5U-m5U-A-C-A-G-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5 [P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N-dimethylaminophosphonamidate], 3[2a-[N2-acetyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl--alanyl-L-arginyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl--alanyl-L-arginyl-6-aminohexanoyl--alanyl], octahydrochloride

EU orphan designation number: EU/3/08/586   
Active ingredient: RNA, [P-deoxy-P-(dimethylamino)] (2,3-dideoxy-2,3-imino-2,3-seco) (2a?5) (C-m5U-m5U-A-C-A-G-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5 [P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N-dimethylaminophosphonamidate], 3[2a-[N2-acetyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl--alanyl-L-arginyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl--alanyl-L-arginyl-6-aminohexanoyl--alanyl], octahydrochloride
Indication: Treatment of Duchenne muscular dystrophy
Sponsor: AVI BioPharma International Ltd
c/o Mazars LLP, Tower Bridge House, St Katharines Way, London E1W 1DD, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/12/2008 Centralised Orphan - Designation EMEA/OD/049/08 (2008)8097 of 03/12/2008